South Korea
· Delayed Price · Currency is KRW BNC Korea Company Description
BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea.
The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia.
It also provides HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, Cutegel Hydro, S-DNA, and H-DNA, which are used to temporarily reduce facial wrinkles through physical restoration; Hibarry, a bio-absorbable gel and solution mixture used to prevent adhesion of the spinal cord post-surgery; and beauty face, and home and other care products under the I.st name.
The company also exports its products to 45 countries. BNC Korea Co., Ltd. was incorporated in 2007 and is headquartered in Daegu, South Korea.
| Country | South Korea |
| Founded | 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 251 |
| CEO | Wan-Gyu Choi |
Contact Details
Address: #405, Structure 1 Daegu South Korea | |
| Phone | 82 70 7116 0059 |
| Website | bnckorea.co.kr |
Stock Details
| Ticker Symbol | 256840 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7256840000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Wan-Gyu Choi | Chief Executive Officer |